AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Revenues flat year on year, but profits up 5% in a year of cost savings and late-stage product disappointments.
You may also be interested in...
EU Pharma Ups Share Buybacks In 2012
Share buybacks are controversial in the biopharma industry, but European pharma companies, facing tough operating environments and pressures on near-term financials, are planning to invest in them in 2012 more than in recent years.
“Arimidex Direct” Program Will Provide Branded Cancer Drug To U.S. Patients For $40 A Month
Spurred on by patient requests for affordable access to the branded version of now generic anastrozole, AstraZeneca will partner with Express Scripts to provide the drug direct to patients at a fixed co-payment.
AstraZeneca Collaboration With Medical Research Council May Mean New Life For 22 Compounds
U.K.-based academic research teams will be able to apply to work with the AstraZeneca compounds free of charge and receive grant funding from MRC under the collaboration.